Censavudine is under clinical development by Transposon Therapeutics and currently in Phase II for Aicardi-Goutieres Syndrome (AGS). According to GlobalData, Phase II drugs for Aicardi-Goutieres Syndrome (AGS) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Censavudine LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Censavudine (Festinavir, BMS-986001,OBP-601) is under development for neurodegenerative diseases like amyotrophic lateral sclerosis, progressive supranuclear palsy (PSP), Aicardi-Goutieres Syndrome (AGS) and frontotemporal dementia (FTD) and Alzheimer's Disease. The drug candidate is administered orally as a capsule. Festinavir is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV-1 reverse transcriptase. It was under development for the treatment of HIV-1 infection.
Transposon Therapeutics overview
Transposon Therapeutics, Inc., a pharmaceuticals company that specializes in developing therapeutics for debilitating and life-threatening diseases. The company is headquartered in United States.
For a complete picture of Censavudine’s drug-specific PTSR and LoA scores, buy the report here.